IMMU.ST Stock - Mendus AB (publ)
Unlock GoAI Insights for IMMU.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $28.49M | $3.00M | $6,000 | N/A |
| Gross Profit | $-6,519,000 | $28.49M | $-1,853,000 | $-1,845,000 | $-1,775,000 |
| Gross Margin | N/A | 100.0% | -61.9% | -30750.0% | N/A |
| Operating Income | $-135,145,000 | $-100,650,000 | $-133,684,000 | $-130,100,000 | $-86,027,000 |
| Net Income | $-128,399,000 | $-101,619,000 | $-136,991,000 | $-136,694,000 | $-92,469,000 |
| Net Margin | N/A | -356.7% | -4574.0% | -2278233.3% | N/A |
| EPS | $-2.64 | $-4.40 | $-0.63 | $-0.68 | $-1.12 |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Visit WebsiteEarnings History & Surprises
IMMU.STEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.66 | $-0.37 | +43.8% | ✓ BEAT |
Q3 2025 | Aug 21, 2025 | $-0.83 | $-0.45 | +45.8% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.54 | $-0.61 | -13.5% | ✗ MISS |
Q1 2025 | Feb 13, 2025 | $-0.72 | $-0.63 | +12.5% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.70 | $-0.46 | +34.3% | ✓ BEAT |
Q3 2024 | Aug 23, 2024 | $-0.62 | $-0.76 | -22.6% | ✗ MISS |
Q2 2024 | May 17, 2024 | $-0.60 | $-0.80 | -33.3% | ✗ MISS |
Q1 2024 | Feb 14, 2024 | — | $-1.12 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.22 | — | — |
Q3 2023 | Aug 29, 2023 | — | $-0.02 | — | — |
Q2 2023 | May 12, 2023 | — | $-0.14 | — | — |
Q1 2023 | Feb 17, 2023 | — | $-0.21 | — | — |
Q4 2022 | Nov 11, 2022 | — | $-0.20 | — | — |
Q3 2022 | Aug 26, 2022 | — | $-0.15 | — | — |
Q2 2022 | May 10, 2022 | — | $-0.14 | — | — |
Q1 2022 | Feb 17, 2022 | — | $-0.17 | — | — |
Q4 2021 | Oct 28, 2021 | — | $-0.17 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.12 | — | — |
Latest News
Frequently Asked Questions about IMMU.ST
What is IMMU.ST's current stock price?
What is the analyst price target for IMMU.ST?
What sector is Mendus AB (publ) in?
What is IMMU.ST's market cap?
Does IMMU.ST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IMMU.ST for comparison